Clearwater has advised Veranex, the first concept-to-commercialisation global service provider dedicated to the MedTech industry, alongside investor Summit Partners, on the acquisition of IMMR, a leading French preclinical services organisation that provides pathology and surgical training services to MedTech innovators.
Headquartered in Paris, France, IMMR is a world-class, market leader in the design and conduct of MedTech and Biotech preclinical studies in large models. Its in-house expertise and state-of-the-art, FDA-inspected and AAALAC International-accredited facilities are unparalleled for successfully completing sophisticated studies with novel interventional or surgical technologies. While the company is perhaps most well-known for its world-leading expertise in complex cardiovascular procedures, IMMR also has broad experience and capabilities across multiple non-cardiovascular disease areas such as ophthalmology, thoracic surgery, neuro-surgery, orthopaedics, dentistry, urology, fetal surgery, and robotics.
Established in June 2021, Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve patients’ lives across the globe. As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide.
